FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011566900> ?p ?o ?g. }

• W2011566900 endingPage "192" @default.
• W2011566900 startingPage "184" @default.
• W2011566900 abstract "A dose-finding study was performed as the first step in the clinical development of the new drug, cizolirtine citrate. To assess the efficacy and safety of cizolirtine citrate in overactive bladder with urinary incontinence. Seventy-nine outpatients with clinical overactive bladder and/or urodynamic diagnosis of detrusor overactivity were randomized in a multicentre, 12-wk, double-blind, pilot trial. Patients received cizolirtine citrate 400 mg bid (C400), cizolirtine citrate 200 mg bid (C200), or placebo. Patients recorded efficacy variables in 7- and 14-d bladder diaries: urinary incontinence episodes, voluntary micturitions, and urgency episodes. The primary efficacy endpoints were changes from baseline to week 12 in average 24-h frequencies of the efficacy variables. Average 24-h frequency of urinary incontinence episodes decreased by a median of 1.14 in C400 versus 0.21 in placebo (p = 0.08). Urgency episodes decreased by a median of 3.00 in C400, by 1.29 in C200 and by 0.43 in placebo (p = 0.004; C400 vs placebo). Cizolirtine showed a clear improvement regarding the percentage of patients free from urinary incontinence episodes at the end of the study, being 68.75% in C400, 45% in C200, and 30% in placebo (p = 0.04; C400 vs placebo). The global efficacy assessment reported by patients showed a clearly favourable opinion (“excellent” or “good”) given by 80% of the patients in C400 and 60% in C200 versus 39% in placebo. Patients reporting adverse events (AEs) were 37% in placebo, 68% in C200, and 81% in C400. The majority of AEs had mild to moderate severity and none was serious. The therapeutic potential of cizolirtine citrate 400 mg bid in overactive bladder has been evidenced." @default.
• W2011566900 created "2016-06-24" @default.
• W2011566900 creator A5001910143 @default.
• W2011566900 creator A5003044910 @default.
• W2011566900 creator A5023771355 @default.
• W2011566900 creator A5024928859 @default.
• W2011566900 creator A5039173177 @default.
• W2011566900 creator A5046912235 @default.
• W2011566900 creator A5090180271 @default.
• W2011566900 date "2009-07-01" @default.
• W2011566900 modified "2023-10-15" @default.
• W2011566900 title "Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study" @default.
• W2011566900 cites W1507174593 @default.
• W2011566900 cites W1967312126 @default.
• W2011566900 cites W1967347194 @default.
• W2011566900 cites W1986323536 @default.
• W2011566900 cites W1994653403 @default.
• W2011566900 cites W1995546742 @default.
• W2011566900 cites W1998527128 @default.
• W2011566900 cites W2012563222 @default.
• W2011566900 cites W2013432695 @default.
• W2011566900 cites W2014075072 @default.
• W2011566900 cites W2032650666 @default.
• W2011566900 cites W2037067579 @default.
• W2011566900 cites W2043742417 @default.
• W2011566900 cites W2053626720 @default.
• W2011566900 cites W2054263301 @default.
• W2011566900 cites W2056717611 @default.
• W2011566900 cites W2058646317 @default.
• W2011566900 cites W2088252790 @default.
• W2011566900 cites W2090330258 @default.
• W2011566900 cites W2090375349 @default.
• W2011566900 cites W2092473900 @default.
• W2011566900 cites W2092749677 @default.
• W2011566900 cites W2147668516 @default.
• W2011566900 cites W2148524234 @default.
• W2011566900 cites W2153390278 @default.
• W2011566900 cites W2162916526 @default.
• W2011566900 doi "https://doi.org/10.1016/j.eururo.2008.04.027" @default.
• W2011566900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18485575" @default.
• W2011566900 hasPublicationYear "2009" @default.
• W2011566900 type Work @default.
• W2011566900 sameAs 2011566900 @default.
• W2011566900 citedByCount "19" @default.
• W2011566900 countsByYear W20115669002012 @default.
• W2011566900 countsByYear W20115669002014 @default.
• W2011566900 countsByYear W20115669002016 @default.
• W2011566900 countsByYear W20115669002018 @default.
• W2011566900 countsByYear W20115669002020 @default.
• W2011566900 countsByYear W20115669002021 @default.
• W2011566900 countsByYear W20115669002022 @default.
• W2011566900 countsByYear W20115669002023 @default.
• W2011566900 crossrefType "journal-article" @default.
• W2011566900 hasAuthorship W2011566900A5001910143 @default.
• W2011566900 hasAuthorship W2011566900A5003044910 @default.
• W2011566900 hasAuthorship W2011566900A5023771355 @default.
• W2011566900 hasAuthorship W2011566900A5024928859 @default.
• W2011566900 hasAuthorship W2011566900A5039173177 @default.
• W2011566900 hasAuthorship W2011566900A5046912235 @default.
• W2011566900 hasAuthorship W2011566900A5090180271 @default.
• W2011566900 hasConcept C126322002 @default.
• W2011566900 hasConcept C126894567 @default.
• W2011566900 hasConcept C142724271 @default.
• W2011566900 hasConcept C168563851 @default.
• W2011566900 hasConcept C197934379 @default.
• W2011566900 hasConcept C202061045 @default.
• W2011566900 hasConcept C204787440 @default.
• W2011566900 hasConcept C27081682 @default.
• W2011566900 hasConcept C2777912814 @default.
• W2011566900 hasConcept C2778531004 @default.
• W2011566900 hasConcept C2778941218 @default.
• W2011566900 hasConcept C2779762690 @default.
• W2011566900 hasConcept C2991744798 @default.
• W2011566900 hasConcept C535046627 @default.
• W2011566900 hasConcept C71924100 @default.
• W2011566900 hasConcept C77411442 @default.
• W2011566900 hasConceptScore W2011566900C126322002 @default.
• W2011566900 hasConceptScore W2011566900C126894567 @default.
• W2011566900 hasConceptScore W2011566900C142724271 @default.
• W2011566900 hasConceptScore W2011566900C168563851 @default.
• W2011566900 hasConceptScore W2011566900C197934379 @default.
• W2011566900 hasConceptScore W2011566900C202061045 @default.
• W2011566900 hasConceptScore W2011566900C204787440 @default.
• W2011566900 hasConceptScore W2011566900C27081682 @default.
• W2011566900 hasConceptScore W2011566900C2777912814 @default.
• W2011566900 hasConceptScore W2011566900C2778531004 @default.
• W2011566900 hasConceptScore W2011566900C2778941218 @default.
• W2011566900 hasConceptScore W2011566900C2779762690 @default.
• W2011566900 hasConceptScore W2011566900C2991744798 @default.
• W2011566900 hasConceptScore W2011566900C535046627 @default.
• W2011566900 hasConceptScore W2011566900C71924100 @default.
• W2011566900 hasConceptScore W2011566900C77411442 @default.
• W2011566900 hasIssue "1" @default.
• W2011566900 hasLocation W20115669001 @default.
• W2011566900 hasLocation W20115669002 @default.
• W2011566900 hasOpenAccess W2011566900 @default.
• W2011566900 hasPrimaryLocation W20115669001 @default.
• W2011566900 hasRelatedWork W1972931270 @default.

• next